Savolitinib shows promise in first-in-human phase 1 study in solid tumours

Results from a first-in-human phase 1 study of savolitinib in 48 patients with locally advanced or metastatic solid tumours was published in Clinical Cancer Research last month. Savolitinib is a selective MET inhibitor. In the study, the maximum tolerated dose was found to be 800 mg daily, and the recommended dose for phase 2 testing […]

read more

Complete response of kidney cancer brain metastases to cabozantinib

A recent case study, reported in Case Reports in Urology, presented an unusual case of a patient with metastatic renal cell carcinoma (RCC) and brain metastases who experienced a complete response to cabozantinib prior to radiation therapy. This case study contributes to the limited evidence on the activity of cabozantinib within the brain. The researchers […]

read more

New drug combination for advanced kidney cancer

Scientists have identified a promising new drug for renal cell carcinoma (RCC); X4P-001 is an oral drug that blocks the cytokine receptor CXCR4. In an ongoing phase 1/2 trial, X4P-001 has been given to patients with advanced RCC in combination with the tyrosine kinase inhibitor axitinib. Preliminary results from the phase 1 part of the […]

read more

HIF-2α inhibitor shows promise in patients with advanced kidney cancer

A recent phase I/II clinical trial with PT2977, a hypoxia-inducible factor (HIF)-2α inhibitor, has shown encouraging anti-tumour activity with a favourable safety profile in patients with previously-treated advanced renal cell carcinoma (RCC). Of the 55 patients who were treated with the HIF-2α inhibitor, 12 patients (22%) had a confirmed partial response. The study is still […]

read more

Bevacizumab plus erlotinib combination for advanced HLRCC

A recent study, published in Cancer Research and Treatment in March 2019, provides the first real-world evidence of the promising treatment of advanced hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare genetic syndrome resulting from mutations in the gene that makes an enzyme called fumarate hydratase. Ten patients with advanced HLRCC-associated renal cell carcinoma […]

read more

ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Toni Choueiri from the Dana-Farber Cancer Institute and Harvard Medical School in Boston, USA, presented updated results from the JAVELIN Renal 101 clinical trial. The results showed that treatment with a […]

read more

Nivolumab plus ipilimumab combination shows survival benefit for patients with untreated kidney cancer at 30 months

Further survival data has been released from the phase 3 CheckMate-214 study, showing that treatment with a combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to demonstrate long-term survival benefits in patients with previously untreated advanced/metastatic renal cell carcinoma (RCC) after 30 months follow-up. Patients with intermediate- and poor-risk untreated RCC treated with the nivolumab/ipilimumab […]

read more

Four distinct subgroups of clear cell renal cancer identified

Using gene profiling, a recent study published in Cancer Discovery has identified four distinct molecular subgroups associated with response to treatment with sunitinib or pazopanib and survival. The findings demonstrate the effects of the presence of immune cells and angiogenesis on the effectiveness of sunitinib and pazopanib against the cancer, and are important for individualised decision-making. […]

read more

Potential of microRNAs as biomarkers for renal cell carcinoma

A recent review of the knowledge about the potential clinical applications of microRNAs (miRNAs) has been published in the Central European Journal of Urology. Specific biomarkers for the early detection and monitoring of renal cell carcinoma (RCC) would enable early diagnosis of the disease. A non-invasive and sensitive biomarker would also be extremely useful for […]

read more
Showing all 9 results
  TOP